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Abstract 
Background 
Pneumococcal diseases cause substantial mortality, morbidity and economic burden. Evidence 
on data inputs for economic evaluations of interventions targeting pneumococcal disease is 
critical. 
 
Objectives 
To summarise evidence on resource use, costs, health utilities and cost-effectiveness for 
pneumococcal disease and associated interventions to inform future economic analyses.  
 
Methods 
We searched MEDLINE, Embase, Web of Science, CINAHL, PsycInfo, Econlit and Cochrane 
databases for peer-reviewed in English studies on pneumococcal disease that reported health 
utilities using direct or indirect valuation methods, resource use, costs or cost-effectiveness of 
intervention programmes, and summarised the evidence descriptively. 
 
Results 
We included 383 studies: 9 reporting health utilities, 131 resource use, 160 economic costs of 
pneumococcal disease, 95 both resource use and costs, and 178 economic evaluations of 
pneumococcal intervention programmes. Health state utility values ranged from 0 to 1 for both 
meningitis and otitis media, and from 0.3 to 0.7 for both pneumonia and sepsis. Hospitalisation 
was shortest for otitis media (range: 0.1 to 5 days) and longest for sepsis/septicaemia (6 to 48). 
The main categories of costs reported were drugs, hospitalisation and household or employer 
costs. Resource use was reported in terms of hospital length of stay and number of contacts 
with general practitioners. Costs and resource use significantly varied between population ages, 
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disease conditions and settings. Current vaccination programmes for both adults and children, 
antibiotic use and outreach programmes to promote vaccination, early disease detection and 
educational programmes are cost-effective in most countries. 
 
Conclusion 
This study has generated a comprehensive repository of health economic evidence on 
pneumococcal disease that can be used to inform future economic evaluations of pneumococcal 
disease intervention programmes. 
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Introduction  
Pneumococcal diseases cause significant morbidity, mortality and economic burden (1-3). 
Infection by pneumococcus is often harmless, but in some individuals the bacterium can evade 
the mucosal surfaces into major organs such as the blood, joints and lungs, leading to serious 
illnesses such as septicaemia, pneumonia and meningitis that often result in hospitalisation, 
complications with long term sequelae, multisystem organ failure or death (4, 5). Other 
common but less serious manifestations include otitis media, sinusitis and bronchitis (6). The 
control of pneumococcal diseases has involved treating infected individuals with antibiotics, 
and infection prevention through the use of paediatric and adult pneumococcal vaccines (7).   
 
Three pneumococcal vaccines are currently being used and these have prevented significant 
disease burden by reducing transmission of the pneumococcus in the population (8). The WHO 
recommends a 23-valent polysaccharide pneumococcal vaccine (PPV23) for adults and at-risk 
groups >2 years, and the 13-valent (PCV13) and 10-valent (PCV10) formulations for infants. 
In 2010, childhood formulations of PCV10 and PCV13 replaced PCV7, which was introduced 
in 2000. Many countries have now introduced pneumococcal vaccination programmes. 
However, the vaccination schedule, coverage and specific details of their implementation vary 
between countries (9). In addition, the different vaccines differ in efficacy and levels of 
protection, as well as price. One of the hallmarks of paediatric vaccinations is the generation 
of indirect effects by the vaccines (10). Pneumococcal vaccines have led to significant 
reduction in disease and carriage due to serotypes covered by the vaccines in unvaccinated 
populations (herd protection) and also significant replacement in carriage and disease due to 
serotypes not covered by the vaccines (serotype replacement) (11, 12).  
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A number of economic modelling studies have been conducted to evaluate the cost-
effectiveness of pneumococcal vaccination and treatment programmes, and these are important 
in helping policy makers make decisions about resource allocation. Preference-based health-
related quality of life outcomes (health utilities) and estimates of economic costs associated 
with pneumococcal diseases and their sequelae are key input parameters to these economic 
models. However, previous reviews on the impact of pneumococcal disease on health-related 
quality of life have only focussed on a small number of pneumococcal infections, such as otitis 
media (13) and sepsis (14). Hospitalisation and long-term sequalae caused by pneumococcal 
diseases have economic consequences at various levels including the individual, household, 
government and overall society. However, no previous systematic review of the global 
economic costs of pneumococcal diseases has been conducted. 
 
Previous systematic reviews of economic evaluations have assessed cost-effectiveness models 
of adult and paediatric pneumococcal vaccination programmes. These reviews  focused on 
parameters and assumptions that influenced modelling results (15), strengths and limitations 
of contributing studies (16), results of cost-effectiveness studies (17, 18), their main 
methodological features (19), economic profiles of vaccines in adults in terms of costs and 
benefits (20), or provided a summary of evidence and key drivers of results in low-and middle 
income countries (21). However, other features, such as modelling methods, input parameters 
and assumptions can affect the generalisability of results. As such, an understanding of 
individual input parameters such as health utility values and economic costs associated with 
pneumococcal disease, as well as key assumptions incorporated into cost-effectiveness 
analyses of preventive and treatment programmes, is critical. To our knowledge, there have 
been no previous systematic reviews of economic evaluations of pneumococcal disease 
treatment and other intervention programmes.  
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We therefore conducted a broad systematic review with the goal of identifying and 
summarising current evidence on health utilities, resource use and economic costs associated 
with pneumococcal disease, and the cost-effectiveness of pneumococcal disease control 
approaches, pneumococcal vaccination and treatment programmes. The findings should be 
influential in informing future economic evaluations in this area.   
Methods 
Search strategy  
We searched MEDLINE, Embase, Web of Science, CINAHL, PsycInfo, Econlit and Cochrane 
using tailored search strategies (see Supplementary Appendix A) for peer-reviewed studies 
published between 1 January 1990 (a decade before any national programmes with conjugate 
vaccine) and 31 November 2016.  
 
Selection criteria and data extraction 
We included studies that reported research on health utilities or other measures of benefit 
valued using economic methods associated with any aspect of pneumococcal disease: invasive 
pneumococcal disease (IPD) that includes meningitis, septicaemia/bacteremia and empyema 
or non-invasive pneumococcal disease that includes community acquired pneumonia, sinusitis 
and otitis media; studies that reported on resource utilisation or costs associated with any aspect 
of pneumococcal disease; and studies reporting an economic evaluation of a preventive or 
treatment intervention for any aspect of pneumococcal disease. Studies reported in languages 
other than English, conference abstracts with no full publication, letters, commentaries and 
systematic reviews were excluded, although the latter were reviewed for potential missed 
studies. 
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Our study selection followed a two-stage process. Initially, two independent reviewers 
performed title and abstract screening to exclude irrelevant studies and, finally, two 
independent reviewers screened full texts to identify relevant articles. Two reviewers 
independently extracted data using standardised data extraction forms from the eligible full 
text studies, and specific details about the extracted data by study type are given in the 
Supplementary Appendix A. At all stages, disagreements between the reviewers were resolved 
by consensus.  
 
Analytical methods 
All cost data were adjusted to 2016 prices and subsequently converted into US dollars using 
purchasing power parities, with both stages of the conversion process applying the Campbell 
and Cochrane Economics Methods Group Evidence for Policy and Practice Information and 
Coordination Centre cost converter (22). When the costing year was not available, it was 
assumed to be the year prior to the publication of the article. We present disaggregated values 
in tabular form for health utilities, resource use and economic costs associated with each 
pneumococcal disease. We also present disaggregated cost-effectiveness results by type of 
adult and childhood vaccination programme, or treatment or other intervention programme. 
Data were not meta-analysed due to heterogeneities in study designs, outcomes and 
intervention types, as well as variations in healthcare practices and relative prices of resource 
inputs, but the results are instead presented in the form of a narrative synthesis. 
 
The methodological quality of selected cost-effectiveness studies was assessed using the 
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist (23), and 
no quality appraisal was conducted for studies reporting health utilities, resource consequences 
or costs. 
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Results 
A total of 25,752 articles were identified by the search strategy, with 383 articles meeting the 
inclusion criteria after the final review stage (see Figure 1). Nine articles reported on health 
utilities, 131 on resource use and 160 on costs associated with pneumococcal disease, with 95 
articles reporting on both resource use and costs. 178 articles reported on economic evaluations 
of pneumococcal intervention programmes. Of these, 50 articles reported on adult vaccination, 
90 on childhood vaccination, 26 on antibiotic treatment and 12 on other intervention 
programmes. 
 
Healthy utility studies 
Nine studies assessed utility values for meningitis, otitis media, pneumonia and 
sepsis/bacteraemia (Table 1 and Supplementary Table S1). These studies were from USA, 
Thailand, Argentina, Chile, UK, and Canada. The results are reported by disease as follows: 
 
Meningitis 
 
Two articles reported on health utility values for meningitis health states using direct valuation 
methods, whilst five reported health utility values for meningitis health states using indirect 
valuation methods (Table 1) (24-30). The health utility values (24-28) ranged from 0.0177 for 
a health state equivalent to death in the USA to 0.9971 for an outcome where blood is drawn 
(USA) (27). One study, using the time trade-off (TTO) method, reported that parents were 
willing to trade up to three years of their own lives to prevent their child from spending any 
time in a meningitis health state and expressed a willingness to pay value of $500 for their child 
to avoid spending time in the described health state (29). 
 
Acute Otitis Media (OM) 
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Two articles reported health utility values for otitis media health states using direct valuation 
methods and two articles reported health utility values for otitis media health states using 
indirect valuation methods (24, 29-31). The health utility values ranged from 0.073 for acute 
otitis media (AOM) with myringotomy in the UK (30) to an overall value of 0.97 in the USA 
(31). One article reported TTO generated time trade-offs ranging from 0-7 days for simple 
otitis media to 270-365 days for complex otitis media, both for the USA, and willingness to 
pay values ranging from $100 to $200 for AOM (29). 
 
Pneumonia 
 
Two articles reported health utility values for pneumonia health states using direct valuation 
methods and two articles reported health utility values for pneumonia health states using 
indirect valuation methods (24, 29, 30, 32). Childhood utility values ranged from 0.44 to 0.73 
in a Thai study (24). One article reported TTO values ranging from 1-180 days for moderate 
pneumonia to 365 days for severe pneumonia, both for the USA (29). The same study reported 
willingness to pay values ranging from $200 to $400 for pneumonia. For adults, health utility 
values ranged from -0.054 for hospitalised pneumonia in Chile (30) to 0.979 for usual health 
in Canada and the USA (32).  Willingness to pay values that measured preferences for the 
location of pneumonia care ranged from 5% for uncomplicated pneumonia care at home to 
30% of monthly household income for complicated pneumonia care at hospital in the USA 
(32). 
 
Bacteraemia 
 
One article reported health utility values for sepsis or bacteraemia using direct valuation 
methods whilst two articles reported health utility values for these health states using indirect 
valuation methods (24, 29, 30). Childhood health utility values ranged from 0.33 to 0.69 in a 
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Thai study (24). One study reported TTO values of 90-180 days and willingness to pay values 
ranging from $250 to $300 for sepsis in the USA (29). For adults, health utility values for sepsis 
or bacteraemia ranged from -0.331 in Chile to -0.034 in Argentina (30).   
 
Cost and resource use studies 
A total of 160 studies reported on the costs of AOM, sinusitis, pneumonia, IPD, meningitis, 
empyema, and sepsis/bacteraemia (see Supplementary Appendix A for tabulated summaries of 
methodological characteristics, results and accompanying references). A total of 131 studies 
reported on resource use by patients with these disease conditions (Supplementary Appendix 
A). Most of the studies were from high-income settings and only 12 studies were from sub-
Saharan African countries. Studies primarily reported on costs of drugs, hospitalisation and 
households, resources use such as hospital stays and visits, and all these varied extensively 
between population ages, settings and disease categories.  
 
Economic evaluations  
In total, 178 articles included in the review were economic evaluations of interventions targeted 
at pneumococcal infections, of which 26 focussed on the impact of antibiotic treatment on 
pneumococcal diseases, 12 focussed on other diagnostic/operational interventions e.g., 
management, treatment guidelines, standing order programmes and screening, and the largest 
number of studies (140) focussed on vaccinations programmes. The vaccination programmes 
were further stratified into adult (Table 2) and paediatric (Table 3) categories. For both adult 
and paediatric programmes, we report assessments of cost-effectiveness of different vaccines 
against no vaccination, vaccine use in different age groups, and head-to-head comparison of 
different vaccines. 
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Vaccination studies 
Adult vaccination 
A total of 50 articles reported economic evaluations of pneumococcal vaccination in adults 
(Table 2 and Supplementary Table S2). Twenty-five studies were carried out in Europe, 17 in 
USA, 2 in Colombia and Brazil, and 1 study in Canada, Japan, China and Hong Kong. Studies 
were grouped by comparisons of different vaccines against no vaccination, vaccine use in 
different age groups and head-to-head comparison of different vaccines as follows:  
 
PPV23 versus no vaccination 
 
Thirty-six articles assessed the impact of PPV23 vaccination against no vaccination, with 
economic results varying from cost saving to a mean incremental cost-effectiveness ratio 
(ICER) of $375,355 per QALY gained (33-68). The time horizon used in these analyses varied 
from one year to a lifetime. Some studies in the USA (34-38), UK (48), Hong Kong (52), 
Belgium (53), Canada (61), China (33), Brazil (63), and Turkey (67) reported that PPV23 use 
in the adult programme dominates in health economic terms.  
 
PCV13 versus no vaccination 
 
Nine studies considered the possible use of paediatric PCV13 vaccine in adult populations 
versus not vaccinating at all (40, 54, 58, 69-74). The economic results varied from cost saving 
overall to a mean ICER of $325,021 per QALY gained. The use of PCV13 in adults over 50 
years of age was cost saving in Spain (69), Colombia (70) and Finland (71). 
 
PCV13+PPV23 versus no vaccination 
 
Two studies from Italy and the USA assessed the cost-effectiveness of a combination or 
sequential use of PCV13 and PPV23 in adults against no vaccination (73, 75). The time horizon 
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considered varied from 5 years to 50 years. The derived mean ICERs varied between $29,607 
and $38,384 per QALY gained. 
 
PPV23 within different age groups 
 
Three studies from the USA (40, 44, 76), one from Japan (77) and another study from Brazil 
(78) assessed the use of PPV23 within different adult age groups. In the USA, targeting 50-
year olds versus all those less than 65 years with comorbidities was extendedly dominated. 
Vaccinating 65-year olds only versus targeting 50-year olds was dominated in health economic 
terms. Targeting 65 and 80 year olds versus targeting 65 year olds only was dominated, 
targeting three age groups (50, 65 and 80 years) versus two age groups (50 and 65 years) was 
extendedly dominated (44), and vaccinating at ≥50 years with PPV23 only versus influenza 
vaccination for all with PPV23 in adults with comorbid conditions was dominated. In Japan, 
vaccinating 65-80-year olds vs vaccinating 65-year olds only was dominated (77). In Brazil, 
universal PPV23 versus targeted PPV23 in high-risk individuals resulted in an ICER varying 
between $970 and $1,392 per life year gained (78).  
 
PCV13+PPV23 versus PPV23 
 
Two studies from the USA evaluated the head-to-head use of a combination of PCV13 and 
PPV23 against the use of PPV23 (75, 79). The models considered time horizons varying from 
15 years to a lifetime. The mean ICERs derived varied between $4,310 and $191,822 per 
additional QALY. 
 
PCV13 versus PCV13+PPV23 
 
Two studies from the USA (40, 41) and one from France (80) assessed the cost-effectiveness 
of using PCV13 versus a combination of PCV13 and PPV23 in adults. The three-time horizons 
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considered were 5 years (France), 15 years and a lifetime (USA). In a study considering a time 
horizon of 15 years, PCV13 alone was dominated when used in immunocompromised adults 
19-64 years of age (40) whereas in a study that considered a lifetime horizon, PCV13 was 
dominant when given to 50 and 65 year olds versus PCV13 at age 50 years and PPV23 at age 
65 years (41). In France, there was a societal net monetary benefit of $85,911,569 as a result 
of using a combination of PCV13 and PPV23 (80). 
 
PCV13 versus PPV23 
 
Six studies estimated the cost-effectiveness of using PPV23 against PCV13 in adults in the 
USA (40, 41), Colombia (70), Spain (81), Germany (58) or the United Kingdom (82). The time 
horizon varied from 5 years to a lifetime in these models. In Colombia and the United 
Kingdom, PPV23 was the optimal strategy, whereas in Germany, PCV13 use in adults was the 
dominant strategy. 
 
Paediatric vaccination 
A total of 90 articles reported the cost-effectiveness of pneumococcal vaccination in children 
(Table 3 and Supplementary Table S3). Thirthy-nine studies were carried out in Europe, 19 in 
Asia, 13 in North America, 24 in South America, 3 in Australia and 7 in Africa, with some 
studies reporting on more than one country. Studies were grouped by analyses of different 
vaccines against no vaccination, vaccine use in different age groups and head-to-head 
comparison of different vaccines as follows: 
 
PCV7 versus no vaccination 
 
The cost-effectiveness of the paediatric PCV7 vaccine versus no vaccination generated 
heterogenous results in different settings. A body of evidence suggested that PCV7 would be 
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cost-effective if indirect effects are included (83). In Finland, PCV7 was deemed not cost-
effective (84). The ICERs ranged between $143 per disability-adjusted life year (DALY) 
averted in resource-limited settings (85) to $47, 392 per DALY averted in Singapore (86), $456 
per QALY gained (87) to $266, 333 per QALY gained (88) in Canada and $242 per life year 
gained (LYG) in Germany (89) to $975, 142 per LYG in Taiwan (83).   
 
PCV10 versus no vaccination 
 
The cost-effectiveness of PCV10 versus no vaccination was assessed in 23 countries, with 
analysis in Canada (90, 91), Colombia (92) and Chile (92) showing that the vaccine was highly 
cost-effective. The mean ICER ranged between $65 per DALY averted in Kenya (93) and $70, 
066 per DALY averted in Croatia (94), with studies in 10 countries (Argentina (95), Brazil 
(92), Gavi-eligible countries (96), Kenya (93), Middle-income countries (97), Malaysia (86, 
98), Mexico (92), Paraguay (99, 100), Peru (92, 101, 102) and Turkey (103)) reporting that 
PCV10 was cost-effective (104). PCV10 use was moderately cost-effective in Singapore (86) 
and not cost-effective in Thailand (105). 
 
PCV13 versus no vaccination 
 
The cost-effectiveness of PCV13 was assessed in 22 countries. The ICERs varied between $51 
per DALY averted in Kenya (93) to $71, 371 per DALY averted in Croatia (94), $3, 147 per 
QALY gained in Philippines (106) to $288, 222 per QALY gained in England (107), and $507 
per LYG in Colombia (108) to $42, 173 per LYG in Taiwan (109). In Japan, PCV13 was cost 
saving (110), whereas the two analyses conducted for England (107, 111), one in Singapore 
(86) and another in Australia (112) showed that PCV13 was marginally cost-effective. In China 
(33) and Thailand (105), the analyses showed that introducing PCV13 into the national 
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immunisation programme was not cost-effective. In Switzerland, including a catch-up 
programme was cost saving compared to not including catch-up (113). 
 
PCV10 versus PCV13 
 
A mixture of results was observed when the two vaccines were compared against each other in 
different settings. Comparison of the cost-effectiveness of PCV10 against PCV13 were 
conducted for 18 countries. In Germany (114), Greece (114), Netherlands (114), Colombia 
(108), Canada (115, 116), Sweden (117), Denmark (117), and Malaysia (118), PCV13 was 
dominant in health economic terms, whereas the analyses for Peru (102), Norway (102), UK 
(119), Hong Kong (120) and Turkey (121) showed PCV10 dominating PCV13.  
 
Assumptions about herd effects and serotype replacement were highly sensitive. Incorporating 
herd effects increases the number of disease cases prevented and serotype replacement that still 
falls below pre-vaccination levels reduced the number of disease cases. 
 
In economic evaluations of vaccination programmes, all 24 quality indicators using the 
CHEERS checklist were assessed, with 37 studies (74%) in adults and 61 studies (68%) in 
children scoring at least a 20 out of 24. 
 
Treatment studies 
Twenty-six studies that estimated the cost-effectiveness of antibiotics for pneumococcal 
diseases CAP, otitis media, sinusitis and empyema were conducted in the USA (14 studies), 
two studies each in the UK and Canada, and one study each in The Netherlands, Germany, 
Italy, India, Malaysia, Belgium, Finland and France, Germany and the USA combined 
(Supplementary Table S4).  
15 
 
 
The studies that compared antibiotics for treating CAP showed that levofloxacin (122-124), 
ceftriaxone (125, 126), combination of moxifloxacin/co-amoxiclav (127, 128), sparfloxacin 
(129), gatifloxacin (130), ampicillin (131), meropenem (132), adherence to IDSA/ATS 
antibiotic guidelines (133), co-amoxiclav (134), azithromycin (135), seven days of home-based 
course of oral amoxicillin (136) and oral gemifloxacin (137) were cost saving. There were no 
significant cost differences between intravenous azithromycin and intravenous erythromycin 
(138), whilst continuous infusion cefuroxime had the same effect but cost less than intermittent 
infusion cefuroxime (139).  
 
For the treatment of otitis media, the following antibiotics were found to be cost-effective: 
ofloxacin (140), amoxicillin (141),  chemoprophylaxis (142), delayed prescription (143, 144), 
and the 2002 antibiotic guidelines (145).  
 
Clinical-criteria guided antibiotic treatment versus no antibiotic treatment and radiography-
guided antibiotic treatment or empirical antibiotic treatment were both cost saving when 
treating sinusitis (146). Computerised tomography with instillation of fibrinolytics was found 
to be cost-effective against percutaneous chest tube for treating empyema (147). 
 
Other interventions studies 
Twelve cost-effectiveness studies of other interventions targeting pneumococcal diseases, 
conducted in the USA (7 studies), Spain (2 studies), The Netherlands (2 studies) and Canada 
(1 study), were identified (Supplementary Table S5). Interventions such as outreach 
programmes to promote vaccination (148), early disease detection and treatment (149), 
procalcitonin protocols in CAP (150), diagnostics (151), patient management (152-155), 
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treatment with guidelines (156), screening (157) and educational programmes (158, 159) were 
found to be cost-effective. 
 
Discussion 
 
We identified a heterogenous body of evidence on health utility values in individuals with 
pneumococcal disease, resource use and economic costs associated with pneumococcal 
disease, and the cost-effectiveness of a range of intervention strategies targeting pneumococcal 
diseases including adult and childhood vaccines, use of antibiotics and other non-medical 
strategies.  This evidence base is growing, especially in high income countries; however, we 
discovered several gaps in the available evidence.  
 
Despite a large number of studies included in this review, we were constrained in our across-
study and country comparisons as contributing studies differed in methodologies, as well as 
underpinning health care practices, relative prices of labour and capital inputs, and preference 
structures for health outcomes. There were relatively few studies on health utilities for 
individuals with pneumococcal disease; in particular, there were no studies from Sub-Saharan 
Africa where the burden of disease and its impact is at its greatest. A particular concern is that 
there is no evidence that estimates the economic burden of disease and its long-term 
consequences in these settings. Amongst the few studies that evaluated health utilities in 
individuals with pneumococcal disease, there was great variability in health utility values, 
ranging across the utility scale for meningitis and otitis media, whereas the utility value range 
for both pneumonia and sepsis was restricted to 0.3 to 0.7. 
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The length of hospital stay was commonly reported and was the major driver of costs in most 
settings. We found substantial variation in hospital stays across different clinical presentations, 
and costs varied significantly between countries, which seriously limits potential 
generalisability across settings. Reporting of cost data sources was not transparent in some 
cases. Our analysis provides evidence on the economic costs of a broad range of pneumococcal 
diseases. 
 
Thirty-six countries assessed the impact of PPV23 against no vaccination in adults, with 
economic outcomes varying from cost-saving to a mean ICER of $355, 355 per QALY gained. 
The cost-effectiveness of PCV13 was assessed in 22 countries, with huge variations in ICER 
values, whilst studies in 15 countries reported that PCV13 was cost saving. Assumptions about 
herd effects and serotype replacement were important. Previous systematic reviews of 
economic evaluations have mainly focused on vaccination programmes (15-21); our 
comprehensive review is distinct in that it focuses on all interventions against pneumococcal 
disease and covers a broad range of pneumococcal disease aspects. 
 
There were no studies from low income countries that assessed the cost-effectiveness of 
treatment for pneumococcal disease with antibiotics. This is a huge concern as antibiotic use 
has increased in low income countries and evidence on the effectiveness of various antibiotics 
is critical for better patient management. These studies from low-income settings should also 
be important as a baseline to monitor the impact on and of increasing antibiotic resistance and 
economic consequences going forward and any interventions against that. 
 
Our review benefits from the inclusion of a range of studies spanning low, middle- and high-
income countries, although we show that there is paucity of data on preference-based health-
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related quality of life outcomes and economic costs in low income settings. Shortfalls of this 
study include the possibility of not finding all relevant studies, particularly given the lack of a 
grey literature search or searches for non-English language papers. We also did not exclude 
studies based on quality. There is an urgent need to conduct studies on the economic burden of 
pneumococcal disease and preference-based health-related quality of life outcomes in low 
income settings with the view to informing future research priorities. Standardisation of 
methods for the measurement and valuation of health utilities and economic costs, and their 
reporting, would enhance across-study comparisons and inform prioritisation strategies of 
global funders. 
 
In conclusion, this review is the first, to our knowledge, to generate comprehensive and 
systematic evidence on health economic aspects of pneumococcal disease. It has generated a 
repository of published evidence on health utilities, resource use, costs and cost-effectiveness 
associated with pneumococcal disease, which should help inform future economic evaluations 
of intervention programmes.  
 
 
Figure caption 
 
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) flow diagram for the literature search. *Note: 95 studies reported on both 
resource use and costs.  
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Table 1: Summary of utility values in pneumococcal infected children and adults. Supporting references are given in parentheses. 
 
Disease Area Age 
Group 
Country Outcome/health state Utility values  
Mean (SD) 
WTP values 
(range) 
TTO 
generated 
time trade-
offs 
Acute Otitis 
Media (AOM) 
Child USA Overall (SG approach) 
0.96 (0.11)(31) 
  
   Overall (TTO 
approach) 0.97 (0.12)(31) 
  
   Simple otitis media  $100(29) 0-7 days(29) 
   
Complex otitis media  $150-200(29) 
270-365 
days(29) 
  Thailand Overall self-report 0.52 to 0.68(24)   
   Overall proxy 0.62 to 0.77(24)   
 Adult Argentina Overall 0.565(30)    
   AOM with 
myringotomy 0.339(30) 
  
  Chile Overall 0.389(30)   
   AOM with 
myringotomy 0.064(30) 
  
  UK Overall 0.391(30)   
   AOM with 
myringotomy 0.073(30) 
  
       
Pneumonia  Child Thailand Overall self-report 0.44 to 0.73(24)   
   Overall proxy 0.48 to 0.70(24)   
  USA Moderate pneumonia  $200-300(29) 1-180 days(29) 
   Severe pneumonia  $400(29) 365 days(29) 
 Adult Argentina Hospitalized 
pneumonia 0.309(30) 
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   Ambulatory 
pneumonia 0.628(30) 
  
  Chile Hospitalized 
pneumonia 
-0.054(30)   
   Ambulatory 
pneumonia 
0.412(30)   
  UK Hospitalized 
pneumonia 
0.035(30)   
   Ambulatory 
pneumonia 
0.508(30)   
  USA & 
Canada Usual health 
0.79 (0.16)(32), 
0.979 (0.084)(32) Not applicable 
 
   
Uncomplicated home 
0.72 (0.18)(32), 
0.994 (0.029)(32) 5% (1-20)(32) 
 
   Uncomplicated 
Hospital 
0.62 (0.19)(32), 
0.993 (0.032)(32) 10% (2-25)(32) 
 
   Delayed response 
home 
0.56 (0.20)(32), 
0.994 (0.029)(32) 10% (2-35)(32) 
 
   Delayed response 
home-hospital 
0.50 (0.18)(32), 
0.993 (0.032)(32) 20% (5-50)(32) 
 
   Delayed response 
hospital 
0.43 (0.19)(32), 
0.993 (0.032)(32) 25% (10-55)(32) 
 
   Complication home-
hospital 
0.27 (0.18)(32), 
0.998 (0.053)(32) 30% (10-75)(32) 
 
   
Complication hospital 
0.28 (0.17)(32), 
0.985 (0.067)(32) 30% (10-80)(32) 
 
       
Meningitis Child Thailand Overall self-report 0.24 to 0.68(24)   
  Thailand Overall proxy 0.02 to 0.52(24)   
  UK Overall 0.181(25), 0.774(26)   
  USA Death 0.0177 (0.07)(27)   
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   Severe brain damage 0.3903 (0.37)(27)   
   Minor brain damage   0.7393 (0.29)(27)   
   Deafness 0.8611 (0.22)(27)   
   Recovery 0.9768 (0.08)(27)   
   Hospitalisation 0.9921 (0.03)(27)   
   Local infection 0.9941 (0.03)(27)   
   Blood drawn  0.9971 (0.02)(27)   
   Overall  $500(29) 2-3 years(29) 
       
 Adult Argentina Overall -0.049(30)   
  Chile  Overall -0.330(30)   
  UK Overall -0.330(30)   
 General 
population 
UK Family member 0.87-0.91(28)   
   Survivor 0.78-0.97(28)   
       
Sepsis or 
Bacteraemia 
Child Thailand Overall self-report 0.33 to 0.69(24)   
  Thailand Overall proxy 0.38 to 0.62(24)   
  USA Overall  $250-300(29) 90-180 
days(29) 
 Adult Argentina Overall -0.034(30)   
  Chile  Overall -0.331(30)   
  UK Overall -0.295(30)   
SG – Standard Gamble, TTO – Time trade-off 
WTP – Willingness to Pay (% of household income/amount of money an individual is willing to pay to avoid described health state) 
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Table 2. Summary of cost-effectiveness studies of pneumococcal vaccination in adults (ICERs valued in $USD, 2016 prices). 
Supporting references are given in parentheses 
 
Comparator  Setting  Results 
PPV23 vs no 
vaccination 
USA PPV23 dominates: (34), (35), (36), (37), (38) 
  PPV23 dominated: (39), (40), (41) 
  ICER falls in NE quadrant:$2,497.94/QALY (42), $33,356.90/QALY, $91,124.42/QALY, 
$96,875.61/QALY (43), $4,269.94/QALY (44), $3,431.43/QALY, $1,959.48/employee 
(45), $9,505.42/QALY, $18,210.27/QALY, $21,664.24/QALY, $28,149.83/QALY (46), 
$72,482.71/LYG, $31,402.47/LYG (47), $45,491.99/QALY, $226,233.43/QALY (38) 
 UK PPV23 dominates: (48) 
  ICER falls in NE quadrant:$375,354.91/QALY (49), $14,441.17-$73,613.17 (50), 
[$19,214.83]/LYG for vaccinating all high risk adults and $17,242.05/LYG for all 65+ year 
olds (51), $16,427.49/LYG (48) 
 Hong Kong PPV23 dominates:(52) 
 Belgium PPV23 dominates (53) 
  ICER falls in NE quadrant: $9,497.91/LYG (53), $158,334.03/QALY, $82,533.95/QALY, 
$61,194.02/QALY (54) 
 Netherlands ICER falls in NE quadrant: $8,163.48/LYG (55), $66,794.34/LYG, $29,923.87/LYG, 
$12,646.40/LYG, $5,521.67/LYG, $1,959.30/LYG, $267.18/LYG (56) 
 Germany ICER falls in NE quadrant: $23,771.12/QALY, $35,781.34/QALY (160), $20,547.77/LYG 
(58) 
 Europe ICER falls in NE quadrant: $14,275.80-$36,554.01 (59), $4,453.32-43,129.81/QALY (60)  
 Canada PPV23 dominates: (61) 
 Italy ICER falls in NE quadrant: $40,346.16/LYG (62) 
 China PPV23 dominates: (33) 
 Brazil PPV23 dominates: (63) 
  ICER falls in NE quadrant: $10,010.24/LYG, $7,614.11/LYG (63) 
 France ICER falls in NE quadrant: $28,428.20/LYS (64) 
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 Poland ICER falls in NE quadrant: $2,102.55/QALY, $1,335.39/QALY (65) 
 Colombia ICER falls in NE quadrant: $1,691.03/LYG (66) 
 Turkey PPV23 dominates (67) 
 Spain ICER falls in NE quadrant: $3,838.65/QALY (68) 
   
PPV23 within age 
groups 
USA ICER falls in NW quadrant: vaccinating 50 years only dominated by vaccinating <65 years 
with comorbidities, vaccinating 65 years only dominated by vaccinating 50 years only, 
vaccinating 65 and 80 years dominated by vaccinating 65 years only, vaccinating 50. 60, 70 
and 80 years dominated by vaccinating 50, 65 and 80 years (44), use of 2 doses dominated 
by 1 dose in immunocompromised individuals 19-64 years (40), Flu only vaccination 
dominated by CDC - influenza vaccination for all and PPV23 when comorbid conditions are 
present, PPV23 only dominated by CDC - influenza vaccination for all, PPV when 
comorbid conditions are present, No vaccination dominated by CDC - influenza vaccination 
for all+ PPV23 when comorbid conditions are present (76) 
  ICER falls in NE quadrant: vaccinating 50 and 65 years vs 65 and 80 years 
[$29,548.34/QALY], vaccinating 50, 60, 70 and 80yrs vs 50, 65 and 80 years 
[$85,396.23/QALY] (44), Flu and PPV23 vs CDC - influenza vaccination for all, PPV when 
comorbid conditions are present [$44,076.64/QALY] (76) 
 Japan ICER falls in NW quadrant: Vaccinating 65yrs only dominated by vaccinating 65-80yrs (77) 
  ICER falls in NE quadrant: Vaccinating >65 years vs 65yrs only[$50.10/QALY] (77) 
 Brazil ICER falls in NE quadrant: universal programme vs targeted programme for high risk 
persons [$1,391.66/LYG], [$969.98] (78) 
   
PCV13 vs no 
vaccination 
USA ICER falls in NE quadrant: $97,038.76/QALY, $307,484.26/QALY, $318,006.54/QALY, 
$73,422.10/QALY, $325,021.39/QALY, $13,211.30/QALY (39) 
 Spain PCV13 dominates (69) 
 Colombia  PCV13 dominates (70) 
 Finland  PCV13 dominates (71) 
 Netherlands ICER falls in NE quadrant: $10,996.34/QALY (72) 
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 Germany PCV13 dominates (58) 
 Italy ICER falls in NE quadrant: $21,602.69/QALY, $24,530.15/QALY, $28,116.43/QALY (73) 
 Belgium ICER falls in NE quadrant: $293,478/QALY, $134,390/QALY, $91, 643.75/QALY (54) 
 UK ICER falls in NE quadrant: herd immunity from infant programme $9, 484.41/LYG (74) 
   
PCV13+PPV23 vs no 
vaccination 
USA ICER falls in NE quadrant: $32,254.95/QALY (75) 
 Italy ICER falls in NE quadrant: $29,606.51/QALY, $33,669.67/QALY, $38,384.21/QALY (73) 
   
PCV13+PPV23 vs 
PPV23 
USA ICER falls in NE quadrant: $4,309.89/QALY, $8,727,087.50/QALY, $131,356.22/QALY, 
$13,813.14/QALY, $4,252.24/QALY  (79), $131,344.12/QALY, $191,821.52/QALY (75) 
   
PCV13 vs PPV23 USA ICER falls in NE quadrant: $33,788.19/QALY (41), $82,935.40/QALY (40) 
 Colombia PCV13 dominated (70) 
 Spain ICER falls in NE quadrant: $2,782.26/QALY (81) 
 Germany PCV13 dominates (58) 
 UK PCV13 dominated (161) 
   
PCV13 vs 
PCV13+PPV23 
USA PCV13 dominated (40) 
  ICER falls in NE quadrant: $52,728.29/QALY (41) 
   
PCV13+PPV23 vs 
PCV13 
USA PCV13 + PPV23 dominated (41) 
  ICER falls in NE quadrant: $579,894.28/QALY (41), $159,849.73/QALY (40) 
 France  PCV13 + PPV23 dominate (80) 
PCV7 – seven valent pneumococcal conjugate vaccine; PCV10 – ten valent pneumococcal conjugate vaccine; PCV13 – thirteen valent 
pneumococcal conjugate vaccine; PPV23 – twenty three valent pneumococcal polysaccharide vaccine; ICER – incremental cost-
effectiveness ratio; NE – north east; NW – north west; QALY – quality adjusted life years; DALY – disabled adjusted life years; LYG – life 
years gained; CDC – Center for disease and control;  
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Table 3. Summary of economic evaluations of pneumococcal vaccinations in children (ICERs valued in $USD, 2016 prices). 
Supporting references are given in parentheses.  
 
Comparator  Setting  Results 
PCV7 vs no 
vaccination 
Taiwan ICER falls in NE quadrant: $975,141.81/LYG, $942,669.62/LYG, $40,047.98/LYG, 
$76,432.95/LYG (83) 
 Norway PCV7 dominates: (162) 
  ICER falls in NE quadrant: $82,683.69/QALY ($54,630.30 if herd immunity is 
included), $183,085.32/LYG ($85,636.68/LYG if herd immunity is included) (163) 
 USA PCV7 dominates: (164) 
  PCV7 dominated: Net benefit -$121,835.59, -$47,072.84, -$20,676.43, -$6,922.48, 
$42,919.35, $16,613.94, -$1,384.50 (165)  
  ICER falls in NE quadrant: $9,328.80/LYG(166), $40,919.96/QALY(167), 
$10,7000/LYG(168), $204,616.52/LYG(169) 
 UK ICER falls in NE quadrant: $63,226.75/LYG(170), $61,679.34/QALY(171) 
 Canada PCV7 dominates: (90), (172), (91) 
  ICER falls in NE quadrant: $129,809.44/QALY, $266,333.15/QALY, 
$226,047.47/QALY (88), $88,156.27/LYG(173), $456.13/QALY (87) 
 Singapore ICER falls in NE quadrant: $47,391.64/DALY(86) 
 Turkey  ICER falls in NE quadrant: $7,627.84/LYG(103) 
 Ireland  ICER falls in NE quadrant: $310,983.05/LYG(174) 
 GAVI-eligible 
countries 
ICER falls in NE quadrant: $196.43/DALY(96) 
 South Korea ICER falls in NE quadrant: $197,630.41/LYG(175) 
 International  ICER falls in NE quadrant: $143.49/DALY(85) 
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 Latin America 
and the 
Caribbean 
ICER falls in NE quadrant: $6,329.04/QALY(176) 
 
 Sweden PCV7 dominates: $34,463.07/LYG(177) 
  ICER falls in NE quadrant: $3,952.85/QALY, $744.16/QALY(178) 
 Finland ICER falls in NE quadrant: $301,658.40/LYG, $193,174.60/LYG(84) 
 Malaysia ICER falls in NE quadrant: $23,078.72/QALY(86) 
 Netherlands ICER falls in NE quadrant: $21,906.11/QALY(179), $36,751.26/QALY(180), 
$19,995.60/QALY(181), $109,369.32/QALY(182) 
 China PCV7 dominates: (183) 
  ICER falls in NE quadrant: $105,114.76/QALY(33), $12,735.68/QALY(184), 
$102,275.72/QALY(185) 
 Middle-income 
countries 
ICER falls in NE quadrant: $1,928.12/QALY(97) 
 Spain PCV7 dominates: -$488.15/LYG(186) 
  ICER falls in NE quadrant: $90,553.87/LYG(187), $36,270.10/LYG(186) 
 Australia ICER falls in NE quadrant: $50,718.33/QALY(112), ($147,240.28: IPD-related 
outcomes only), ($80,479.16-$111,573.38: changes in non-IPD included) and 
$8,230.82 : changes in adult non-invasive pneumonia are included(188), 
$138,735.75/QALY(189) 
 Germany  PCV7 dominates: -$833.43/QALY (healthcare),-$6,752.66/QALY (societal) (190) 
  ICER falls in NE quadrant: ?72866/LYG(191), $56,434.57/LYG, $242.15/LYG, 
$148,588.50/LYG(89) 
 Japan ICER falls in NE quadrant: $16,011.63/QALY(110), $91,368.33/QALY(192) 
 Colombia ICER falls in NE quadrant: $879.19/LYG(193) 
 Peru  ICER falls in NE quadrant: $6,666.58/QALY(102) 
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 Switzerland ICER falls in NE quadrant: $29,053.05/QALY(194) 
 Argentina ICER falls in NE quadrant: $6,376.83/QALY(195) 
 Italy  ICER falls in NE quadrant: $27,991.68/DALY(196) 
 The Gambia ICER falls in NE quadrant: $1,096.62/DALY(197) 
 Hong Kong ICER falls in NE quadrant: $10,287.71/LYG, $9,441.95/LYG(198) 
 Brazil  ICER falls in NE quadrant: $825.91/DALY(199) 
 Chile  ICER falls in NE quadrant: $2,511.31/DALY(199) 
 Uruguay  ICER falls in NE quadrant: $1,922.98/DALY(199) 
 Malaysia ICER falls in NE quadrant: RM35,196/LYG(200) 
PCV9 vs no 
vaccination 
The Gambia ICER falls in NE quadrant: $36.15/DALY(201), $807.40/DALY(197) 
PCV10 vs no 
vaccination 
Canada PCV10 dominates: (90), (91) 
 Croatia  ICER falls in NE quadrant: $70,066.45/DALY(94) 
 Brazil  ICER falls in NE quadrant: $4,613.43/QALY (societal), $5,279.84/DALY (healthcare) 
(104), $3,725.50/QALY(92) 
 Argentina ICER falls in NE quadrant: $9,946.66/DALY, $9,473.33/DALY(95), 
$3,298.03/QALY(92) 
 Singapore  ICER falls in NE quadrant: $49,390.25/QALY(86) 
 Turkey  ICER falls in NE quadrant: $7,279.12/LYG(103) 
 GAVI-eligible 
countries 
ICER falls in NE quadrant: $134.97/DALY(96) 
 Malaysia  ICER falls in NE quadrant: $24,882.39/QALY(86), $23,471.96/QALY(98) 
 Netherlands ICER falls in NE quadrant: $24,718/QALY(180) 
 Colombia  PCV10 dominates: (92) 
  ICER falls in NE quadrant: $843.24/LYG(108), $2,036.33/LYG(202) 
 Chile  PCV10 dominates : (92) 
  ICER falls in NE quadrant: $7,917.55/QALY(92) 
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 Mexico  ICER falls in NE quadrant: $4,491.51/QALY (92) 
 Peru  ICER falls in NE quadrant: $5,092.86/QALY(92), $1,690.99/DALY(101), 
$4,988.30/QALY(102) 
 Middle-income 
countries 
ICER falls in NE quadrant: $1,205.07/DALY(97) 
 
 Australia ICER falls in NE quadrant: $39,245.32/QALY(112) 
 Philippines  ICER falls in NE quadrant: $3,936.43/QALY(106) 
 Paraguay ICER falls in NE quadrant: $4,268.87/DALY, $2,128.34/DALY(99), 
$2,770.10/DALY(100) 
 The Gambia ICER falls in NE quadrant: $807.40/DALY(197) 
 Georgia  ICER falls in NE quadrant: $1,657.65/LYG(203) 
 Thailand ICER falls in NE quadrant: $46,738.69/QALY(105) 
 Ecuador ICER falls in NE quadrant: $1,619.63/DALY(100) 
 Honduras ICER falls in NE quadrant: $2,464.13/DALY(100) 
 Kenya ICER falls in NE quadrant: $64.61/DALY(93) 
PCV13 vs no 
vaccination 
Taiwan ICER falls in NE quadrant: $42,173.26/LYG, $20,284.62/LYG(109) 
 Croatia ICER falls in NE quadrant: $71,370.93/DALY(94) 
 England ICER falls in NE quadrant: marginally cost-effective (111), $288,222.01/QALY(107) 
 Argentina ICER falls in NE quadrant: $12,135.97/DALY, $11,650.44/DALY(95) 
 Singapore ICER falls in NE quadrant: $41,224.98/QALY(86) 
 Turkey ICER falls in NE quadrant: $7,184.70/LYG(103) 
 GAVI-eligible 
countries 
ICER falls in NE quadrant: $126.53/DALY(96) 
 Egypt ICER falls in NE quadrant: $4,059.63/DALY(204) 
 Malaysia ICER falls in NE quadrant: $20,332.14/QALY(86) 
 Netherlands ICER falls in NE quadrant: $23,488/QALY(180) 
 Colombia ICER falls in NE quadrant: $507.19/LYG(108) 
 Peru  ICER falls in NE quadrant: $1,373.86/DALY(101), $5,905.03/QALY(102) 
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 China  ICER falls in NE quadrant: $29,748.93/QALY(33) 
 Middle-income 
countries 
ICER falls in NE quadrant: $1,084.57/DALY(97) 
 
 Australia ICER falls in NE quadrant: $43,251.33/QALY(112) 
 Japan PCV13 dominates: (110) 
 Philippines ICER falls in NE quadrant: $3,147.09/QALY(106) 
 Paraguay ICER falls in NE quadrant: $5,432.81/DALY, $4,053.82/DALY(99) 
 The Gambia ICER falls in NE quadrant: $686.89/DALY(197) 
 Thailand ICER falls in NE quadrant: $47,456.68/QALY(105) 
 Kenya ICER falls in NE quadrant: $51.47/DALY(93) 
 Spain ICER falls in NE quadrant: $15,863.02/QALY(205) 
PCV7 vs PCV10 Colombia  PCV7 dominates: (202) 
   
PCV10 vs PCV7 Canada  PCV10 dominates: (90), (91), (116) 
 Peru  PCV10 dominates: (206) 
 Turkey  PCV10 dominates: (121) 
   
PCV7 vs PCV13 Japan PCV7 dominated: (110) 
 Canada  PCV7 dominated: (116) 
   
PCV13 vs PCV7 Germany PCV13 dominates: (114) 
 Netherlands ICER falls in NE quadrant: $49.50/QALY(114) 
 Norway PCV13 dominates: (162) 
 USA PCV13 dominates: (207) 
 Switzerland PCV13 dominates: (113) 
 Peru  ICER falls in NE quadrant: $2,020.81/QALY(102) 
 Turkey PCV13 dominates: (121) 
   
PCV13 vs PCV10 Germany  PCV13 dominates: (114) 
 Greece  PCV13 dominates: (114) 
 Netherlands PCV13 dominates: (114) 
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  ICER falls in NE quadrant: $833,665.01/QALY(208) 
 Peru PCV13 dominated: (102) 
  ICER falls in NE quadrant: $13.95/avoided hospitalisation(206), $546.81/DALY(101) 
 Argentina ICER falls in NE quadrant: $31,201.23/DALY, $30,610.40/DALY(95) 
 Colombia PCV13 dominates: (108) 
 Canada  PCV13 dominates: (115), (116) 
 Sweden  PCV13 dominates: (117)  
  PCV13 dominated: (209) 
 Denmark  PCV13 dominates: (117) 
 Malaysia  PCV13 dominates: (118)  
  ICER falls in NE quadrant: $5,211.38/QALY(118) 
PCV10 vs PCV13 Philippines  ICER falls in NE quadrant: $3,000.80/QALY(210), $930.95/QALY(106) 
 Norway PCV10 dominates:(162)  
 Canada  PCV10 dominates: (119)  
 UK PCV10 dominates: (119)  
 Hong Kong  PCV10 dominates: (120)  
 Colombia ICER falls in NE quadrant: $10,548.58/LYG(202) 
 Malaysia  PCV10 dominates: (98) 
 Turkey  PCV10 dominates: (121) 
PCV13: catch-up vs 
no catch-up 
Switzerland  Catch-up dominates: (113) 
 Italy  ICER falls in NE quadrant: $17,358.18/YLS(211) 
   
PCV13: 2 dose vs 3 
dose 
USA ICER falls in NE quadrant: $321,895.05/QALY(212) 
 
PCV7 – seven valent pneumococcal conjugate vaccine; PCV9 – nine valent pneumococcal conjugate vaccine; PCV10 – ten valent 
pneumococcal conjugate vaccine; PCV13 – thirteen valent pneumococcal conjugate vaccine; 
ICER – incremental cost-effectiveness ratio; NE – northeast; QALY – quality adjusted life years; DALY – disabled adjusted life years; LYG 
– life years gained; IPD – invasive pneumococcal disease
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